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Short running title:  Argon neuroprotection in neurological injury  
 Summary 
Despite the global burden of brain injury, neuroprotective agents remain elusive. There are no 
clinically effective therapies which reduce mortality or improve long-term cognitive outcome. 
Ventilation could be an easily modifiable variable in resuscitation; gases are relatively simple 
to administer. Xenon is the prototypic agent of a new generation of experimental treatments 
which show promise. However, use is hindered by its prohibitive cost and anaesthetic 
properties. Argon is an attractive option, being cheaper, easy to transport, non-sedating and 
mechanistically distinct from xenon. In vitro and in vivo models provide evidence of argon 
reducing brain injury, with improvements in neurocognitive, histological and biomarker 
metrics, as well as improved survival. Current data suggests the effect of argon is mediated via 
the toll-like receptors 2 & 4, the ERK 1/2 and PI-3K-AKT pathways. Ventilation with argon 
appears to be safe in pigs and preliminary human trials. Given recent evidence that arterial 
hyperoxia may be harmful, the supplementation of high-concentration argon may not 
necessitate changes to clinical practice. Given the logistic benefits, and the evidence for argon 
neuroprotection summarised in this manuscript, we believe that the time has come to consider 
developing Phase II clinical trials to assess its benefit in acute neurological injury. 
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Glossary 
CA  Cardiac Arrest 
HIE  Hypoxic-ischemic encephalopathy 
TBI  Traumatic brain injury 
CPR  Cardiopulmonary resuscitation 
CT  Computer tomography 
MRI  Magnetic resonance imaging 
NMDA  N-methyl-D-aspartate 
GABA  γ-Aminobutyric acid 
OOHCA Out-of-hospital cardiac arrest  
HO-1  Haem-oxygenase 1 
NQO-1 NADPH dehydrogenase (quinone 1) 
GST  Gluthatine S-transferases  
SOD-1  Superoxide dismutase 1 
OGD  Oxygen glucose deprivation  
tMCAO Transient middle cerebral artery occlusion 
ARE  Anti-oxidant response element 
FIO2  Fraction of inspired oxygen 
ROS  Reactive oxygen species 
TLR  Toll-like receptor 
tMCAO Temporary middle cerebral artery occlusion 
OGD  Oxygen-glucose deprivation 
ICU  Intensive care unit 
VF  Ventricular fibrillation 
 
  
Introduction: Neuroprotection with conventional pharmacological agents has failed.  
Neuroprotection for brain injury, though conceptually attractive and experimentally effective, 
has been a clinical failure. Neurological injury is the mode of death after two-thirds of out-of-
hospital cardiac arrests (CA) and one-third in hospital.1 Most die during their initial hospital 
admission.2 Furthermore, two-thirds of patients who survive have moderate to severe cognitive 
deficits three months after their CA.3 Neurological injuries such as hypoxic brain injury 
following CA, stroke, ischaemic stroke, neonatal hypoxic-ischemic encephalopathy (HIE) and 
traumatic brain injury (TBI) are among the leading causes of global mortality and morbidity.4-
7 Poor functional outcomes from such injuries are commonplace, meaning around half never 
return to work.8 These statistics highlight the importance of developing therapeutic strategies 
which are aimed at providing ‘neuroprotection’.9  
In any acute neurological insult, we can attempt to reverse the primary process which leads to 
brain injury (e.g. thrombolysis for ischaemic stroke, or surgical or medical therapy of 
intracranial hypertension). Early thrombolysis in stroke can greatly improve functional 
outcomes, despite significant contra-indications and drawbacks including haemorrhagic 
transformation.10 Public education has significantly improved rates of early and appropriate 
bystander cardiopulmonary resuscitation (CPR).11 12 However, there are virtually no therapies 
which protect injured brain tissue (described generically as ‘neurons’) that have been starved 
of oxygen (hypoxia), and consequently reduce mortality or improve long-term cognitive 
outcome.13 While established as an effective treatment in neonatal hypoxic-ischemic 
encephalopathy (HIE), the benefits of therapeutic hypothermia in adults is still uncertain, 
particularly regarding precise temperature thresholds for benefit.14-17 Furthermore, despite 
cooling, half of neonates with HIE still die or suffer significant neuro-developmental 
disability.6 18 19 New strategies are needed. Altering how patients are ventilated could be an 
easily modifiable variable in resuscitation. More accurately targeting oxygen administration 
(preventing hyperoxia), along with additive gaseous agents, have been suggested.  
 
Pathophysiological mechanisms of secondary neurological injury  
The causes of brain injury are heterogeneous. Broadly, they include primary brain injury either 
caused by a lack of intra-cerebral vascular supply (i.e. stroke), trauma, and hypoxic ischaemic 
injury following cardiac arrest. While this review will mention specific causes of brain injury, 
each with varying mechanisms, substantial commonality exists in the pathophysiology that 
drives secondary neural injury following each of these insults, suggesting a basis for common 
therapies aimed at these.  
Secondary neuronal injury drives ongoing damage occurring after the initial insult has 
occurred. Proposed mechanisms include: reperfusion injury following a period of ischaemia20, 
neuroinflammation within the salvageable penumbra,21 breakdown of the blood-brain barrier21, 
disruption and remodelling of the cerebral microvasculature,22 excitotoxic injury23 and 
oxidative stress owed to excessive free-radical production.23-26 27-30 
 
The noble gases represent plausible neuroprotective candidates; xenon is the prototypic 
agent 
The noble gases, including argon and xenon, have acquired significant interest as potential 
neuroprotective agents with promising in vitro and in vivo data.31 While typically thought of as 
‘inert’ because of their filled valence shell, noble gases can create physiological effects by Van 
der Waals forces, providing enough energy to form a bond in a given binding site.32 Xenon, 
with the most outer electrons, has the greatest polarising effect. This has been correlated with 
its anaesthetic ability.32 Atomically heavier than argon, xenon has been used as an anaesthetic, 
as a contrast agent in both computer tomography (CT) and magnetic resonance imaging (MRI), 
as well as a candidate neuroprotectant (especially, in neonates33). Like all gases, it can quickly 
cross the blood-brain barrier, increasing its clinical potential.34  
Xenon is thought to function in neuroprotection by antagonism of the NMDA receptor, thereby 
preventing glutamate mediated excitotoxic stress.35 36 Most current evidence suggests xenon 
acts by the competitive inhibition of glycine, a co-agonist of the NMDA receptor;37 although 
some propose involvement of the adenosine triphosphate dependent potassium channels.34 The 
addition of exogenous glycine tends to abolished neuroprotection by xenon in vitro.36 38 
However, at least two mutations in the NMDA receptor eliminate xenon binding without 
affecting the affinity of glycine.39 Another study demonstrated inhibition of NMDA currents 
irrespective of glycine concentration.40 These data suggest a complex and yet incompletely 
elucidated mechanism of xenon.  
Irrespective of this, good neuroprotective data have also been demonstrated with Xenon, to the 
point of phase II human clinical trials.33 41 Laitio et al. demonstrated encouraging radiological 
evidence of benefit with xenon in humans after out-of-hospital cardiac arrest (OOHCA), 
combined with therapeutic hypothermia.42 In this study, the severity of white matter injury on 
diffusion tensor MRI was significantly reduced at 16 hours after rewarming. Global fractional 
anisotropy (a marker of white matter integrity), the primary outcome measure, was 3.8% higher 
in the xenon group compared to controls. Anisotropy has previously been shown to be one of 
the best independent predictors of mortality after CA.43-47 While radiological evidence alone is 
not sufficient to draw significant conclusions about human efficacy, Phase II studies are being 
planned, and these data provide conceptual evidence for neuroprotection from noble gases.  
However, clinical use of xenon is limited by its expense and that it is an anaesthetic at sea level. 
There have been several human studies into surgical xenon use, including cost-analyses.48-52 
There is significant regional variation in the price of xenon from $60/L in US to $30/L in 
France,48 far higher than the often miss-quoted $10/L, which is now historic.53 The price of 
xenon is inelastic: increases in consumption beyond its fixed capacity (or supply ceiling) will 
increase its price.54 Further increases in production will be expensive. Closed-circuit 
recirculation and recycling ventilation systems are therefore required for cost efficiency (Table 
1). Consequently, xenon is unlikely to be feasible in emergency care settings where ease of use 
is a priority. This is especially true in a pre-hospital setting where limited equipment is 
available. Irrespective of the context, a xenon based ventilator system is currently not 
commercially available. Additionally, the sedative effects of xenon could confound assessment 
of conscious level and neurological state.55 56 
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Cost and utilisation 
To maintain a 50-70% Xe or Ar concentration 
Approximate cost pre-hospital 
 
Approximate cost in hospital 
 
Argon 
2.71¢/L 
 
Open flow rate: 
Steady state use: 10L/min or 6,000L/hr
a
 
= 27.1¢/min (at 2.71¢/L) 
= $16.3/hour 
 
Closed circuit flow rate: 
no data 
 
Open flow rate for ~2-4 hours
b
: 
= 24,000L over 4 hours 
Cost: $65 
 
Open flow (24h): 20,880L 
Cost: $390 
 
Closed circuit (24h): ~211L
c
 
Cost: $5.72 
Xenon 
$30-60/L 
Open flow rate: 
not feasible 
 
Closed circuit flow rate
d
: 
Steady state use: 5.0-12.5L/h 
Averaged use of 8.8L/h, at $30/L 
= $264/h 
 
Use not feasible 
 
Open flow (24h): not feasible 
 
Closed circuit (24h): ~211L
e
  
Cost: $6,330 (at $30/L)  
 
Table 1 - A cost-comparison of argon and xenon using the current data available 
a
Approximate figure, inferred from historic use oxygen and xenon in the literature as part of a 15L/min non-rebreathe flow rate 
b
 Approximate time to xenon administration in Phase 
II trial.
42
 
c
 Roughly equivalent to xenon: Broad et al. (2016) describe use of 4-5L/minute to ventilate piglets; adult humans would require more. Alderliesten et al. (2014) report a 
similar rate in personal communication. 
d 
Ventilation flow rate inconsistently reported (variables include the ventilation equipment and its scavenging efficiency, the gas-mix 
required, and the use of other anaesthetic agents); data primarily from elective adult surgery using Xenon as an anaesthetic agent. 
48 - 53 
One additional publication reports flow rates 
of as low as 0.52 L/h using a custom-made ventilation device, but this was in the context of neonates with neonatal encephalopathy
52
 and has not been integrated into this graphic.
 e 
based 24 hours of steady state flow at 8.8L/h, not accounting for higher rates possibly required in the induction phase. 
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Argon is an attractive alternative and is likely to be mechanistically distinct from xenon 
Argon is a potential alternative to xenon.  A comparison of the neuroprotective properties of 
the two agents in past publication suggested the superiority of xenon, but only included a 
limited number of argon studies.57 This was in contradistinction to a review in 2014,58 which 
more fully summarised the data on argon neuroprotection available up to 2013, and suggested 
that argon showed promise as a clinical neuroprotectant. We build on these two reviews by 
providing a more up to date survey of the literature (our search strategy is included as 
Supplementary data) and suggest the next steps for translational neuroprotection studies in this 
manuscript. 
Nearly two decades have passed since Soldatov first demonstrated the protective effects of 
argon in hypoxia.59 Since then, growing evidence has suggested argon could have a role in 
human neuroprotection. Argon fulfils the criteria of being easy to administer and transport, 
cheap (Table 1) and with few proven side-effects.55 The cost of argon has been cited as 
approximately 9¢/L in previous literature (e.g. Loetscher et al. 2009). However, as of 3.1.17 
The BOC Group plc (U.K.) cost for medical grade argon (suitable for patient consumption; 
99.99% purity1) was £233.25 for a 50L cylinder containing 10,570L gas. This equates to 
2.21p/L (GBP). Equivalent, on the same date, to 2.71¢/L (USD). Argon is far more abundant, 
a fact that explains low costs and, consequently, negates the requirement for expensive and 
cumbersome rebreathing circuits. In addition, it has no hypnotic effects at sea-level is also only 
an anaesthetic at hyperbaric pressures.56 60 
Argon appears to have a spectrum of anti-apoptotic qualities, which are distinct from the 
modulation of neurotransmitters (NMDA) and prevention of excitotoxicity attributed to 
xenon.40 More specifically, argon does not appear to mediate neuroprotection through effects 
at GABA61or NMDA36 receptors, or TREK136 and KATP62 channels. 
Instead, argon appears to prevent cell death via upregulation of both the ERK 1/2 and PI-3K-
AKT pathways (Figure 1). 6 63-66 From these two pathways, a common series of mediators 
stimulate a set of downstream effectors including anti-oxidant response elements (AREs). 
Inhibition at the point of ERK 1/2, PI-3K-AKT, the mediator molecules mTOR and nuclear 
factor (erythroid-derived 2) factor 2 (Nrf-2), or its AREs, using small molecules or SiRNA, all 
appear to block the neuroprotective effects of argon in vivo.64-68 Cytotoxic damage itself also 
                                                          
1 BOC Product code: 290469-L-PC. 
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stimulates the ERK 1/2 pathway, in the context of in vivo models of hypoxic brain injury.65 
Small molecule inhibition of the pathways increased the quantity of cell death and the 
expression of pro-apoptotic mediators.65 69 The PI-3k-AKT pathway induces a cellular survival 
signal in opposition to apoptosis.70 71 Therefore, it seems likely that argon is stimulating 
endogenous cellular protection pathways with the result of preventing cellular stress and 
eventual apoptosis. 
Argon has been shown to work synergistically with hypothermia through common pathways, 
including PI-3K-AKT, in models of neonatal hypoxic brain injury. In contrast, pro-
inflammatory pro-apoptotic signalling molecules including GSK3b, cytochrome c and caspase 
3 are all inhibited by argon and hypothermia.6 72
11 
 
 
Figure 1 - A cartoon to illustrate the hypothesised molecular mechanisms 
of argon, synthesising the current available literature.6, 59, 60-76 
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Nrf2, a basic leucine zipper transcription factor, appears to mediate this pathway.73 74 Normally 
Nrf2 is bound to Keap-1 (Kelch-like ECH-associated protein 1), and this leads to Nrf2 
ubiquitination and proteasome degradation. However, oxidative stress inhibits Keap-1 
repression of Nrf2, and so leaves it free to translocate to the nucleus where it can protect against 
oxidative stress by upregulating the expression of ARE’s.67  
Downstream effector molecules of this common anti-apoptotic pathway include NADPH 
dehydrogenase (quinone 1), glutathione S-transferases, superoxide dismutase 1 and Haem-
oxygenase 1 (HO-1).6 73 The last of these, Haem-oxygenase 1, is usually induced by oxidative 
stress, and catabolises free heme (an oxidant) into labile iron (Fe2+), carbon monoxide and 
biliverdin.6 75 76 Each of these breakdown products elicits individual anti-apoptotic effects. For 
example, carbon monoxide interacts with the p38 MAPK pathway, leading to the degradation 
of the pro-apoptotic molecule, p38a; and production of the protective molecule, p38b, which 
induces Bcl-2 (an anti-apoptotic molecule).75 Despite evidence for an important role of HO-1 
in argon-mediate neuroprotection,6 others have shown an initial reduction in HO-1 protein 
concentration in retinal ganglion cells after argon ventilation.65 Significant work remains to 
elucidate the downstream effectors of argon. Irrespective, the upregulation of a set of 
superoxide scavenger molecules explains argons association with reduced signs of oxidative 
stress. 
Other studies show involvement of toll-like receptors (TLR) 2 and 4 upstream of the ERK 1/2 
signalling pathway.77 Typically characterised as signalling receptors participating in the innate 
immune system, TLRs are thought to have an important, but unclear, role in neurons. TLR 4 
has previously been demonstrated in vitro to mediate apoptosis; inhibition of it appears to 
protect against apoptosis.78 79 Similarly, Ulbrich et al. used rotenone to induce oxidative 
damage, which induced upregulation of the TLR 2 and 4 receptors. In vitro retinal ganglion 
culture, and in vivo after retinal ischemic reperfusion injury, argon ventilation helped avert 
oxidative damage. At 75% argon concentration, there was a marked upregulation of the ERK 
1/2 pathway and a decrease in NK-kB expression.65 77 80 Blocking of the TLR 2 and 4 signalling 
pathway by the small molecule OxPAPC prevented argon-mediated cytoprotection and ERK 
1/2 expression.77 80 It is not clear if argon is acting on the TLRs, potentially preventing their 
role in apoptosis, or affecting a parallel pathway. Certainly, argon has been shown to 
downregulate a variety of pro-apoptotic proteins, such as caspase 3.80 81 
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Efficacy of argon in in vitro models of neurological injury 
Substantial in vitro data support the neuroprotective effectiveness of argon (Table 2), primarily 
using the oxygen and glucose deprivation (OGD) model of hypoxic-ischemic injury in neuronal 
culture.55 
After OGD, a high-concentration argon-containing media confers a survival benefit to both 
dissociated cultures of murine cortical neurons82 and ex vivo organotypic hippocampal slice 
preparations,55 with better preservation of cellular and dendritic morphology.6 A dose-
dependent improvement in survival has also been demonstrated.55 77 Even during unstressed 
conditions, cultured neurons survive better in an argon atmosphere compared to nitrogen.82 
Intriguingly, neon, krypton and helium either had no benefit or potentiated injury, in model 
systems.82  
Argon shows neuroprotection in related settings.  It reduced damage by up to 25% in murine 
cochlear hair cells subjected to hypoxia, cisplatin or gentamycin toxicity,83 and reduced injury 
by up to 80% in a stylus drop model of TBI in organotypic hippocampal slices, with protection 
maintained following a two-hour delay to administration, and some residual protection 
following a three hour delay.55 
Molecular analysis in these in vitro models show that argon modulates proposed target 
pathways, with broad upregulation of anti-apoptotic mediators during and after OGD. This 
includes the upstream pathways PI-3K-AKT and ERK 1/2, mediators such as mTOR and Nrf2, 
and downstream effectors like HO-1.6 64-66 77 It appears that inhibition at any stage along this 
cascade reverses the benefits that argon appears to provide.6 66 Conversely, argon 
downregulates pro-apoptotic and pro-inflammatory molecules, including cytochrome c, 
caspase 3, NFkB and GSK3b. Argon treatment appears to reduce the concentration of reactive 
oxygen species (ROS).66 
These in vitro data support a role for argon neuroprotection, which is dose related and persists 
in large part despite delays to intervention, and provide a useful basis for translating argon 
neuroprotection to in vivo models.  
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First 
author 
Disease 
Model 
Animal Treatment protocol Treatment 
group gas 
mix 
Control 
group 
gas mix 
Cell survival data Histopat
hological 
data 
Biomarker analysis 
Zhao 
2016 
OGD Cortical 
neuronal 
cultures 
(gestational 
day 16 rat 
foeti) 
OGD for 90 min with 
treatment gas bubbled 
through media, then 
incubated with treatment 
for 2h; with (33°C) or 
without (37°C) 
hypothermia; incubated in 
normal media for further 
24h. 
75% Ar, 
20% O2, 5% 
CO2 
75% N2, 
20% O2, 
5% CO2 
Increased percentage of live cells 
by around 50% 
 
Improved 
cellular 
and 
dendritic 
cell 
morpholog
y. Reduced 
caspase 3 
positive 
areas. 
Significant upregulation of HO-1 and p-
AKT by Ar, maximally at 4h but 
significantly sustained for 24h. 
Hypothermia also upregulated HO-1 and 
p-AKT, which was further enhanced by 
Ar. Suppression of p-GASK-3β and 
mitochondrial cytochrome c release was 
also significantly increased. Inhibition of 
either HO-1 or p-AKT prevented argon 
mediated protection. 
Zhao 
2016 
OGD Cortical 
neuronal cell 
culture 
(gestational 
day 18 rat 
foeti) 
OGD for 90 min with 
treatment gas bubbled 
through media, then 
incubated with treatment 
for a further 24h 
70% Ar, 
25% O2, 5% 
CO2 
70% N2, 
25% O2, 
5% CO2 
 Preserved 
neuronal 
morpholog
y and cell 
viability 
using Ar, 
assessed 
via MTT 
assay. 
Ar induced upregulation of Erk 1/2, PI-3K 
and p-mTOR after OGD challenge. 
Increased expression of Nrf2 and its 
translocation to nuclei; along with 
downstream antioxidant response elements 
(e.g. SOD-1, NQO1). Experimental 
inhibition of m-TOR and Nrf2 abolished 
the effect of Ar. Reduced caspase-3 
cleavage after OGD with Ar (suggesting 
increased cell-survival). 
Ulbrich 
2015 
Oxidativ
e stress  
Human 
neuroblastom
a cell line 
(SH-SY5Y) 
Rotenone treatment for 
4h, then exposure to Ar 
for 2 or 4h 
75%, 50% or 
25% Ar, 
with 21% 
O2, made up 
with N2 
Room air Maximal benefit observed using 
75% Ar, reducing apoptosis to 
baseline. Benefit of Ar time and 
dose dependent. 
Significant
ly 
reduction 
in TLR-2 
& TLR-4 
receptor 
density and 
protein 
expression 
with Ar 
treatment. 
Induction of ERK 1/2 pathway by Ar, and 
caspase-3 activity decreased. Inhibition of 
TLR signalling prevented this. Small 
molecule inhibition of ERK 1/2 and TLR 
receptor signalling prevented the benefits 
of Ar treatment. 
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David  
2012 
OGD  Ex vivo rat 
striatal brain 
slices 
Glucose free solution 
saturated with 100% 
nitrogen for 20 min; 3h 
treatment. 
25-75% Ar, 
25% O2, 
remaining 
percent N2 
Medical air 
(75% N2, 
25% O2) 
  Significant reduction in LDH release, as a 
marker of cell injury, using 37.5-75% Ar 
(maximal at 50%, after 3h). 
Fahlenkamp  
2012 
N/A Mouse 
primary 
cortical 
neurons, 
microglia and 
astrocytes 
Exposure to humified gas 
mixture for 15, 30, 60 or 
120 min. 
50% Ar, 
24% N2, 
21% O2, 5% 
CO2 
Humified 
room air 
  Significant induction of ERK 1/2 in 
microglia, maximal at 30 min. A similar 
induction in neurons and astrocytes did not 
reach statistical significance. 
Jawad 
2009 
OGD Mouse 
cerebral 
cortices, 
dissociated 
neurons 
OGD for 90 min with 
nitrogen (95%, with 5% 
CO2) or noble gas, then 
treatment for further 24h. 
75% noble 
gas (e.g. Ar), 
20% O2, 5% 
CO2 
75% N2, 
20% O2, 
5% CO2 
  Cell viability (judged by reducing ability 
via MTT assay) preserved after OGD 
using Ar & Xe, but not neon, krypton or 
helium. In the absence of OGD, Ar even 
improved cell viability. 
Loetscher 
2009 
OGD and 
TBI 
Ex vivo 
mouse 
hippocampal 
tissue 
OGD for 30 min or 
subjected to stylus 
dropped with identical 
force, then experimental 
media for 72h, added 
either immediately or with 
2h or 3h delay. 
Media had 
25%, 50% 
and 74% Ar, 
with 21% 
O2, 5% CO2 
and N2 to 
top-up 
Humified 
room air 
Ar decreased tissue injury 
significantly after OGD and TBI; 
maximum benefit observed using 
74% & 50%, respectively. Reduced 
benefit after a delay in treatment, 
although still significantly reduced 
injury. 
  
Yarin 
2005 
Hypoxia Cultured 
organ of 
Corti cells 
from rats 
Nitrogen or Ar hypoxia; 
Toxic drug exposure with 
cisplatin or gentamycin 
Hypoxia: 
95% Ar, 5% 
CO2, Drug 
exposure: 
74% Ar, 
21% O2, 5% 
CO2 
Hypoxia: 
95% N2, 
5% CO2, 
Drug 
exposure: 
74% N2, 
21% O2, 
5% CO2 
Approximate 20-30% reduction in 
cell death with Ar treatment during 
hypoxia, cisplatin and gentamycin 
exposure. 
 
  
Table 2 - A comprehensive summary of the literature with the results of in vitro data pertaining to the use for argon ventilation for neuroprotection 
 
TBI: traumatic brain injury, OGD: oxygen-glucose deprivation, Ar: Argon, TLR: Toll-like receptor 
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Efficacy of argon in whole animal models of HIE, stroke and CA 
Several studies, in multiple species and a range of experimental models, provide evidence of 
argon neuroprotection, using varying concentrations and duration of argon exposure and delays 
to initiation of treatment (Table 3).  
 
Cardiac arrest models in vivo 
Post-resuscitation ventilation for 1 hour with a 70% argon + 30% oxygen mixture significantly 
improved functional and histological outcomes in a ventricular fibrillation model of cardiac 
arrest in rats,84 with improved cognitive function during seven days of follow up and less 
neuronal damage in the neocortex and hippocampus. This benefit was additive to that derived 
from post-arrest ventilation using controlled oxygen levels (using a 70% nitrogen & 30% 
oxygen mixture in the comparator group).84 These data, and a dose dependency of argon 
neuroprotection in this model, were replicated in a larger sample size by the same group.62 
Furthermore, they have demonstrated that despite a delay in treatment by 3 hours, argon still 
confers significant neuroprotection, in terms of reduced histopathological damage and 
improved functional recovery.85 If observed in humans, this benefit will have significant 
clinical advantages. 
The efficacy of argon has also been replicated pigs using balloon occlusion of the left anterior 
descending coronary artery to induce ventricular fibrillation.86 Following an eight-minute 
period of circulatory standstill, the animals were defibrillated and mechanically ventilated for 
4 hours, with either argon/oxygen or argon/nitrogen mixtures. The argon group had 
significantly better cognitive scores, displaying little cognitive impairment at 24 hours after 
arrest. After 72 hours, pigs treated with argon had returned to pre-test cognitive levels, whereas 
control pigs had only recovered 75% of baseline function. Elevation in neuron specific enolase 
(a neuronal injury marker) and neuropathological evidence of neuronal injury were both 
attenuated in the argon group.  Argon does not appear to have significant independent effects 
on systemic haemodynamics and ventilation56 86 or cerebral oxygen saturation and brain 
electrical activity.56 
A more recent study from Zuercher et al (2016) failed to replicate the neuroprotective benefits 
of argon.87 Compared to Brucken85 and Ristagno86 et al., however, ROSC was achieved in the 
Zuercher study 20% and 35% quicker, respectively, which was correlated with less severe 
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impairment in neuropsychological testing. In addition, both Brucken and Ristagno use 70% 
argon and 30% oxygen and a different method of inducing cardiac arrest (induction of VF by 
electrical stimulation or balloon occlusion of the left anterior descending coronary artery vs. 
potassium and esmolol) and ROSC (defibrillation vs. manual CPR). Many of these differences 
were recognised by Zuercher et al.87 We speculate that the differences between studies in this 
context relates to a reduced benefit of argon (and perhaps any neuroprotectant) when the index 
insult results in relatively mild neuropsychological deficits and/or histological injury.  
  
Stroke models in vivo 
An ischaemia reperfusion model of retinal artery occlusion showed that argon significantly 
reduced the damage of retinal ganglion cells.65 Two studies using the transient middle cerebral 
artery occlusion (tMCAO) model of stroke in rats demonstrated smaller overall infarct volumes 
and better composite behaviour outcomes after 50% argon treatment initiated an hour after 
occlusion (to mimic a clinical timeline). However, there was no survival benefit seen, and 
cytokine analysis was not conclusive.63 88 The effects of argon in this setting seem complex. A 
further tMCAO study found that 50% argon reduced cortical infarct volume by 35%, but 
increased subcortical damage by 35%.89 However, these results are confounded using 100% 
O2 as an anaesthetic carrier, which may have had independent deleterious consequences, given 
the association with hyperoxia worsening reperfusion injury.90 91 
Another study modelled subarachnoid haemorrhage using perforation of a cerebral artery, 
leading to a sharp rise in intracranial pressure and a drop in regional cerebral blood flow.60 
Administration of 50% argon for an hour reduced the risk of premature death by 20% after 3 
days. While neurocognitive assessments did not differ, rats in the treatment group appeared to 
have better general health and less neuronal damage (judged by mean body weight and NeuN 
positive nuclei, respectively).  
 
Neonatal HIE models in vivo 
Hypothermia has been successfully used to treat HIE but has limitations. Recent in vivo 
evidence suggests that argon may not only have a role in neuroprotection after hypoxic brain 
injury in neonatal mammals, but also enhances the benefit of hypothermia.6 Carotid artery 
ligation has been the method most commonly used to model this. 
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In two studies of neonatal HIE using carotid artery occlusion with hypoxia, Zhao et al. showed 
that neonatal rats treated with 2 hours of 70% argon had significantly reduced infarction 
volumes.6 66 When combined with hypothermia, the addition of argon therapy reduced the 
average infarction volume in a temperature dependent manner (by 48% at 37°C and 65% at 
33°C), compared to nitrogen at normothermia.6 Argon also reduced weight loss and cerebral 
reactive gliosis.6 66 At a molecular level, argon neuroprotection was associated with 
upregulation of Nrf2, ARE downstream effector molecules (e.g. HO-1) and reduced evidence 
of oxidant injury (e.g. malondialdelyde) in penumbral tissue.6 66 Argon’s apparent benefit in 
reducing histopathological damage and inducing ‘anti-apoptotic’ expression were blocked by 
in vivo inhibitors of either PI-3K-AKT (Wortmannin) or ERK 1/2 (U0126),66 suggesting a 
requirement for both pathways. 
Argon neuroprotection in HIE was replicated by Broad et al. in a neonatal piglet model of HIE, 
where the addition of 45-50% argon, initiated 2 hours post-insult and administered for 24 hours, 
resulted in benefit that was additive to induced hypothermia (33.5°C).18 Cerebral biomarkers 
were suggestive of reduced brain injury, including reduced white matter lactate and increased 
whole brain adenosine triphosphate and phosphocreatine. The argon group also showed 
improved mean hourly electroencephalogram recordings, suggesting faster recovery of brain 
activity. Both findings have been associated with better neurodevelopmental outcomes.92-94  A 
survival benefit was not assessed, as piglets were euthanised at 48 hours. 
Put together, these results show a translation of the positive benefits shown in vitro to animal 
CA and stroke models. Arguably most importantly, cognitive testing showed clear beneficial 
differences in argon treatment groups. This is corroborated by histological and biomarker data. 
Limitations in the literature, such as small sample sizes and inconsistent experimental 
conditions, prevent more specific conclusions, for example, about the optimal argon-oxygen 
mix. Considering its potential, the safety of argon needs to be assessed before human trials can 
be commenced, and such evidence is now beginning to accumulate.
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First 
author 
Disease 
Model 
Animal Treatment 
protocol 
Treatment 
group gas 
mix 
Control 
group 
gas mix 
Mortality 
data 
Neuro-cognitive 
assessment 
Histopathological data Biomarker analysis 
Ischaemic Stroke 
Broad  
2016 
Stroke Piglet Bilateral carotid 
artery occlusion for 
12.5 minutes. 
Initiation of 
ventilation from 2h 
till 26h. 
Simultaneously 
cooled to 33.5°C 
50% Ar, 
29% N2, 
21% O2 
(with 
variable 
oxygenation 
to maintain 
SaO2 8-
13kpa.) 
Not 
specified 
  Reduced TUNEL+ 
staining. However, only 
noted in certain brain 
areas, e.g. putamen not 
periventricular white 
matter. 
White matter lactate 
significantly lower in 
hypothermia and Ar group. 
Increased whole brain ATP 
and phosphocreatine at 48 
hours. Improved mean 
hourly EEG recordings. 
Ulbrich 
2015 
Stroke (retinal 
ischaemia) 
Rat 1h ischemia caused 
by increased ocular 
pressure. Then 1h of 
treatment, 
immediately or with a 
1.5 or 3h delay. 
75% Ar, 
with 21% 
O2, 4% N2 
Room air   Inhibition of ERK 1/2 
attenuates Ar-mediated 
protection  
Ar ventilation significantly  
increased ERK 1/2 
expression and HSP 70. In 
contrast, decreased protein 
levels of HO-1 and HSP-90 
Ulbrich 
2014 
Stroke Rat 1h ischemia followed 
by 1h of treatment, 
immediately or 
without a 1.5 or 3-h 
delay.  
75%, 50% or 
25% Ar, 
with 21% 
O2, made up 
with N2 
Room air   Retinal ganglion cell loss 
was reduced by Ar in a 
dose and time dependent 
manner. Optimal at 75%, 
the benefits at this level 
were largely maintained 
with a 1.5h delay. 
Ar inhibited NF-kB, Bax 
and Bcl-2 expression 
significantly 
 
Ischemic induced 
leucocytosis reduced 
significantly  
Fahlenkamp 
2014 
Stroke Rat tMCAO for two 
hours, ventilation 
started 1h later for 1h 
50% Ar 
50% O2 
50% N2 
50% O2 
No survival 
benefit noted 
Improved 
composite 
behaviour outcomes 
Reduced infarct volumes Mixed cytokine production 
on a spectrum of 
neuroprotection (TGF- β, 
NGF) and pro-inflammation 
(IL-1β, IL-6) 
David 
2012 
Stroke Rat Stereotaxic striatal 
injection of NDMA 
Or 1h tMCAO, 
followed by 3h of 
treatment 
15-75% Ar, 
25% O2, 
remaining 
percent N2 
Medical air 
(75% N2, 
25% O2) 
 Minimal difference 
in behavioural 
outcomes between 
groups. 
Reduced neuronal damage 
with all concentrations of 
Ar, maximally at 50% 
(NMDA condition). Ar 
reduced cortical brain 
damage (35%) but 
increased subcortical 
 
20 
 
damage (35%) after 
tMCAO. 
Ryang  
2011 
Stroke Rat tMCAO for 2h; 
ventilation started 1h 
later for 1h 
50% Ar 
50% O2 
50% N2 
50% O2 
No survival 
benefit 
within 24h 
Improved 
composite 
behaviour outcomes 
Reduced infarct volume  
Cardiac arrest & global cerebral hypoxia 
Zuercher 
2016 
Cardiac arrest Rat Cardiac arrest 
induced by potassium 
and esmolol. 8 
minutes arrest, 
followed by manual 
chest compressions 
with intravenous 
adrenaline. Ventilated 
for 24h after ROSC 
50% Ar, 
50% O2, or 
50% He, 
50% O2 
50% N2, 
30% O2 
 No difference in 
NDS over 5 days 
Trend (non-significant) to 
reduced hippocampal 
neuronal damage in the 
noble gas treated groups.  
 
Brucken 
2015 
Cardiac arrest Rat VF induced by 
transoesophageal 
electrical stimulation. 
Defibrillation after 7 
minutes, ventilated 
for 1h either 1h or 3h 
after ROSC 
70% Ar, 
30% O2, 
70% N2, 
30% O2 
 Improved NDS at 7 
days, in Ar treated 
group in both the 1 
hour and 3-hour 
delay groups. 
Significantly more 
mobile episodes 
only in the delayed 
group.  
Significant reductions in 
neuronal damage index in 
hippocampal and 
neocortical samples. Rats 
in the 3h delay group also 
showed significant 
reductions in basal ganglia 
damage, compared to 
controls. 
 
Ristagno 
2014 
Cardiac arrest Pigs Balloon Occlusion of 
LAD to induce VF. 
Defibrillation after 8 
minutes of VF, 
ventilated for 4h 
70% Ar, 
30% O2 
70% N2, 
30% O2 
 After 72h, pigs 
treated with Ar had 
returned to pre-test 
cognitive levels, 
whereas control 
pigs had only 
recovered 75% of 
baseline function 
Significantly reduced 
neuronal damage 
Significantly reduced 
Neuron-specific enolase 
Brucken 
2014 
Cardiac arrest Rat VF induced by 
transoesophageal 
electrical stimulation. 
Defibrillation after 7 
minutes, ventilated 
for 1h after 1h 
70% Ar with 
30% O2, or 
40% Ar with 
30% O2 
70% N2, 
30% O2 
 Improved NDS at 7 
days, with a dose 
dependent 
improvement (70% 
> 40%). 
Significantly more 
Neocortex and 
hippocampal slices showed 
significantly less neuronal 
damage, irrespective Ar 
concentration 
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mobile episodes in 
open field test only 
using 70% Ar. 
Brucken 
2013 
Cardiac arrest Rats VF induced by 
transoesophageal 
electrical stimulation. 
Defibrillation after 7 
minutes, ventilated 
for 1h after 1h 
70% Ar, 
30% O2 
70% N2, 
30% O2 
 Improved NDS at 7 
days. More mobile 
episodes in open 
field test, 
inconclusive 
improvement in 
water maze. 
Neocortex and 
hippocampal slices showed 
significantly less neuronal 
damage. 
 
Miscellaneous animal models  
Hollig  
2016 
Subarachnoid 
haemorrhage 
Rat Cerebral artery 
perforation. 
Treatment started 1h 
after induction, for 1h 
50% Ar, 
50% O2 
50% N2, 
50% O2 
20.6% 
reduction in 
‘premature 
death’ at 72h 
No difference Mean body weight greater 
in Ar group. Significantly 
greater NeuN positive 
nuclei in some Ar brain 
slices (dendate gryus, 
specifically). Cerebral 
odema equivocal between 
groups. 
HIFα1 increased at 24h ours 
with Ar, compared to 
controls (but not 6h or 72h) 
Zhao 
2016 
Neonatal HIE  Rat 
(neonatal) 
Carotid artery 
ligation. 1h after 
induction, 2h 
treatment, with (33°C 
or 35°C) or without 
(37°C) hypothermia  
70% Ar, 
30% O2  
70% N2, 
30% O2 
  Reduced infarction volume 
by up to 65% when used 
synergistically with 
hypothermia (vs N2 and 
37°C). 
 
Reduced glial activation 
(GFAP expression) 
Ar significantly reduced 
caspase 3 expression beyond 
hypothermia alone. Ar 
induces p-AKT and HO-1 
and inhibits NF-kβ 
expression. Inhibition of 
HO-1 and p-AKT abolishes 
the benefit of Ar 
 
Alderliesten 
2014 
Safety 
evaluation; 
hypoxic 
ventilation 
mixture 
administered 
Pig #1 Ventilation with increasing 
concentrations of Ar, 1h each (30%, 
50%, 80%) 
#2 1h of hypoxia (FiO2 0.08) 
followed by 3h of 50% Ar 
#3 As above, with hypothermia (34-
35°C) 
Immediate 
euthanasia 
for 
histology 
 No demonstrable 
increase neuronal 
injury in normoxia 
due to Ar 
No significant change in 
heart rate, mean arterial 
pressure, regional cerebral 
saturation of oxygen or 
electroencephalography 
due to Ar ventilation 
 
Zhuang 
2012 
Neonatal HIE Rat 
(neonatal) 
Common carotid 
artery ligation 
followed by hypoxic 
70% Ar, He 
or Xe, with 
30% O2 
70% N2, 
with 30% 
O2 
 No significant 
difference in 
Ar treatment restored the 
cell number in hippocampi 
to that of naïve rats; Xe 
Ar and Xe treated rats 
sustained their body weight 
despite carotid ligation. 
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atmosphere (8% O2) 
for 90 or 120 
minutes. Treatment 
initiated 2h after, for 
1.5h 
neurological 
function testing. 
and helium to a lesser 
benefit. Approximate 40% 
decrease in infarction size 
by Ar and Xe (no 
protection by helium) 
However, helium treatment 
further reduced body weight. 
Bcl-2 expression 
significantly increased with 
Ar, and to a lesser degree 
helium and Xe. 
 
 
 Table 3 - A comprehensive summary of the literature with the results of in vivo data pertaining to the use for argon ventilation for neuroprotection  
 
NDS: neurological deficit score, ROSC: return of spontaneous circulation, tMCAO: transient middle cerebral artery occlusion, HIE: hypoxic-ischemia 
encephalopathy, LAD: left anterior descending, VF: ventricular fibrillation, Ar: argon, HSP: Heat-shock protein 
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The safety of argon in larger animal models and humans 
Xenon has been used safely in human anaesthesia,49 51 radiology,95 neonatology (up-to 50% 
xenon concentration)52 and now in a phase II clinical trial.42 The human use of argon has been 
far less studied. In a major step forward, Alderliesten and colleagues demonstrated the 
haemodynamic safety of argon in a porcine model.56 Anaesthesia was achieved with a standard 
human protocol, with argon up to 80% concentration. Oxygen was used to maintain normoxia 
on arterial blood gas. This was largely kept at 21% O2, with occasional temporary increases 
required during mucus plugging, for example (Groenendaal F., Personal Communication, 2014). 
The rest of the gas mixture contained nitrogen. Argon did not cause significant changes in heart 
rate, mean arterial blood pressure, regional cerebral saturation of oxygen or 
electroencephalography.  
Giving pause for caution, two historic studies using argon to achieve pneumoperitoneum in 
adult pigs demonstrated an increase in systemic vascular resistance.96 97 A negative effect on 
cardiac output was demonstrated in one,96 but then not replicated.97 Neither showed any effect 
from argon on respiratory function, mean arterial pressure, nor acid base-balance. Given these 
date, further studies into the use of argon for ventilation should carefully monitor for signs of 
cardiovascular compromise. 
Argon has been used before in humans, in the context of developing safe breathing mixtures. 
Concentrations of 79% were historically (1970’s) used to measure coronary blood flow and is 
a recognised diving mixture.56 In a more recent study, argon was tested to see if it altered the 
rate of oxygen consumption during physical exercise in a hypoxic environment (15% O2).
98 
Seven healthy males cycled whilst breathing mixtures containing either 0%, 30% or 85% argon. 
Investigators found an increased oxygen consumption with greater argon concentrations, 
compared to nitrogen-dominated mixtures. However, both at rest and during exercise, there 
were no differences in the peripheral capillary saturation of blood haemoglobin measured using 
pulse oximetry. Therefore, it was concluded that differences in pulmonary gas exchange and 
tissue oxygenation were not the cause of increased oxygen consumption. The authors suggested 
that this may represent an enhanced ability for humans to tolerate hypoxia while breathing 
argon-containing mixtures. 
Another study evaluated the effect of argon on cognitive performance.99 Over six days, four 
volunteers first breathed ‘normoxic’ mixtures of oxygen, nitrogen, argon and carbon dioxide 
(14%, 33%, 54% and 0.24%, respectively,). After this, they spent three days in ‘hypoxic’ 
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conditions (10% O2). Unsurprisingly, breathing ‘normoxic’ gas improved cognitive task 
performance. Subjectively, study participants reported increased vigour and decreased 
fatigability in ‘normoxia’. In addition, ‘normoxia’ did not decrease the long-term retention of 
learnt skills. 
These trials provide a basis for further confirmation of the safety of argon in humans. Argon 
will need to be supplemented only when appropriate oxygen requirements allow it to be used 
at concentrations that deliver neuroprotection. 
 
Some caveats and confounds for human translation: the impact of hyperoxia 
Many trials of argon have used concentrations more than 50%. In the past, this would have 
required a change in clinical practice as it was common to use high inspired oxygen fractions 
(FIO2) as a part of resuscitation, often reaching 100% oxygen. However, more recent concerns 
regarding hyperoxic injury have led to reduced use of FIO2 higher than that needed to deliver 
normal oxygenation.30 100-104 The routine supplementation of oxygen is no longer advised by 
national guidelines after acute stroke,105 106 though larger trials are ongoing.107 In myocardial 
infarction, the recent AVOID trail showed that unnecessary supplementary oxygen exacerbated 
myocardial injury.108 109 
In vivo data show hyperoxia after CA increased ROS production25 and lipid oxidation,110 and 
exacerbation of neuronal death.24 111 When appropriate, limiting FIO2 to 50% after CA can 
reduce oxidative stress, and has shown improvements in myocardial function and survival.29 A 
canine CA model showed significantly better neurological outcome and neuronal histology 
having targeted physiologically normal oxygen saturations.90 91 Consistent experimental 
evidence,110 112 113 including a meta-analysis published in 2012,103 conclude animal evidence 
clearly points to worse neurological outcomes after hyperoxia. 
In humans, epidemiological studies amongst intensive care patients have shown arterial 
hyperoxia is independently associated with an increased in-hospital mortality after stroke,114 
TBI,115 CA,102 and all-comers.116 This data, as well as two recent meta-analyses, provide 
evidence that arterial hyperoxia is associated with poor functional neurological outcomes, in a 
dose-dependent manner.100 101  
Feasibility and safety studies have supported the use of conservative oxygen management in 
appropriate intensive care patients, associated with shortened lengths of hospital stay.116 117 
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This evidence suggests argon can be used safely in high concentrations in acute neurological 
compromise, with appropriate titration of oxygen in dynamic gas mixtures. Trials into the 
neuroprotective benefit of argon must include standard-of-practice control groups, ensuring 
any benefit observed is not simply from a reduced rate of hyperoxia in the argon treated group. 
Notwithstanding this, a proportion of patients who have compromised gas exchange after 
neurological injury (e.g. due to pulmonary aspiration or heart failure) may require a high FiO2 
to achieve arterial normoxia, and the use of argon for clinical neuroprotection may be 
inappropriate in these subjects. 
 
A route to translational neuroprotection with argon  
Both xenon and argon have shown promise as neuroprotective agents, with improvements in 
histological, biochemical and cognitive outcomes. Xenon has a well-documented track record 
in this regard, which has culminated in Phase II trials,42 and a planned Phase III trial.118  
However, xenon is relatively scarce and expensive, which necessitates closed-circuit 
ventilation systems and limits its use in out-of-hospital settings, thus delaying the onset of 
neuroprotective benefit.48 53 In addition, the anaesthetic effects of xenon provide a benefit in 
perioperative settings and in contexts where sedation is desirable.  However, these properties 
may hamper clinical neurological assessment.35 51 54 Perhaps more importantly, the fact that 
xenon may be a cerebral vasodilator119 120 limits its use in patients with (or at risk of) 
intracranial hypertension, thus excluding many patients with acute neurological injury 
(particularly TBI).  
The literature reviewed in this manuscript suggests that argon has significant neuroprotective 
effects, which may be comparable to xenon. It does not have anaesthetic properties at the 
concentrations used (and hence, if used in the prehospital setting, would not confound 
neurological assessment at hospital arrival).32 Further, although data are limited, it has no 
known vasodilatory effects on the cerebral circulation (avoiding the risk of exacerbating 
intracranial hypertension). The key elements of translation are summarised in Figure 2.  
Perhaps most important of the drivers to attempt to develop argon as a neuroprotective agent 
is the fact that it is a more logistically tractable agent than xenon. Argon is cheap (3¢/L) and 
easy to transport, meaning open-flow ventilation would be economically acceptable.  
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Translational development of argon as a neuroprotective agent could be informed by additional 
experimental studies that addressed dose-response-relationships, identification of the most 
effective dose and duration of administration, most effective time-point of administration in 
relation to the insult.  However, this route to clinical neuroprotective translation has not had 
any signal successes in the past.  If argon is safe, an alternative translational philosophy121 
suggests that, given the past failures in neuroprotective translation, there is a case for initiating  
early clinical studies alongside such preclinical refinement, since the maximum delivered 
concentration, time point for administration, and duration of administration in clinical studies 
are constrained by clinical and logistic realities.   
A more relevant consideration, however, is to address the practicalities of effectively delivering 
the intervention. Minimal changes in equipment would be required, although a method of 
titrating the mixed gases (oxygen and argon) would be needed. In addition, there may be a need 
to recalibrate ICU ventilators to account for differences between argon and nitrogen, with 
respect to density, viscosity and thermal conductivity,122 as has been required with helium.123 
Figure 2 - A graphic demonstrating the important factors in the clinical 
implementation of argon as a neuroprotective treatment for brain injury 
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Robust evidence will be required that titrating oxygen supplementation to peripheral oxygen 
saturations is safe, as has been demonstrated with xenon.42 Direct measurement of argon in gas 
mixtures is possible,124 but not currently clinically routine, and dosing would need to rely on 
measurement of other gases in inspired gas mixtures.  While direct measurement is not essential 
to proceed with clinical trials, this would be desirable. Safety testing will also need to ensure 
sufficient ventilation of ambulances (and other closed environments) exist to ensure first-
responder paramedics are not at risk of hypoxia. Providing these caveats are addressed, the pre-
hospital use of argon would be plausible.86  
Given these logistic benefits, and the evidence for argon neuroprotection summarised in this 
manuscript, we believe that the time has come to think about Phase II clinical trials to assess 
its benefit in acute neurological injury.  Some initial safety data may be required before such 
studies can be fully planned and eventually implemented, particularly in terms of longer 
exposures in larger animals (which would be needed for regulatory approval). Similar human 
data from healthy volunteers is already available from a small cohort of volunteers (n=4), 
showing that exposure to 50% argon is safe for up to six days;99 replication and extension of 
this study would be useful, along with the assessment of effects on cerebral blood flow (using, 
for example, transcranial Doppler ultrasound, or MRI with arterial spin labelling).  Given the 
potential commercial returns from this initiative, it would not be unreasonable to ask the 
vendors of noble gases for human use to generate an investigational medicinal product dossier 
(IMPD) available for argon (which is a prerequisite for entering into clinical trials in humans). 
While further refinement will clearly be needed, Table 4 provides a starting point for design of 
Phase II studies in candidate patient groups.   
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Patient group Primary neuroprotection in patients with cardiac arrest, stroke or traumatic brain 
injury. 
Peri-operative neuroprotection in patients undergoing cardiopulmonary bypass or 
neurosurgical intervention for aneurysmal subarachnoid haemorrhage). 
Interventions Initial target argon concentration 50% with nitrogen and oxygen 
- Ideally initiated in pre-hospital phase for primary neuroprotective trials, continued 
for 3-5 days 
- As part of anaesthetic regime for perioperative neuroprotection, and consider 
ongoing postop use for 3-5 days.  
Controls Nitrogen used as a comparator gas. The FiO2 of the control group needs to be the 
same as the treatment group. 
Outcomes Circulating biomarkers (NSE, S100b; especially for perioperative neuroprotection – 
may be confounded by injury heterogeneity in primary neuroprotection studies), 
Neuroimaging (e.g. conventional and diffusion tensor MRI; especially with serial 
imaging to demonstrate change over period of neuroprotection) 
Clinical outcomes – not likely to be a primary end point in Phase II studies, but will 
need assessment, using validated instruments tailored to indication (e.g. Glasgow  
Outcome Score-extended for TBI; modified Rankin scale for stroke) 
Table 4 - A P.I.C.O. model for a randomised control phase 2 trial into the effectiveness of argon in neuroprotection.  
NSE: Neuron-Specific Enolase, MRI: Magnetic resonance imaging, TBI: Traumatic brain injury, FiO2: Fraction of inspired oxygen 
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